Wall Street analyst estimates for Dr. Reddy's Laboratories Limited (RDY): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Dr. Reddy's Laboratories Limited, alongside its associated companies, functions as a holistic pharmaceutical entity with a global footprint. Its business operations are divided into several key divisions. The Global Generics segment is responsible for the manufacturing and sale of both prescription and over-the-counter finished pharmaceutical products.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-10-23 | $0.10 | ||
| 2026-07-21 | $0.06 | $0.09 | -34.7% |
| 2026-05-11 | $0.06 | $0.09 | -33.3% |
| 2026-01-20 | $0.16 | $0.16 | +0.0% |
| 2025-10-24 | $0.19 | $0.18 | +5.6% |
| 2025-07-23 | $0.20 | $0.18 | +11.1% |
| 2025-05-09 | $0.22 | $0.20 | +10.0% |
| 2025-01-29 | $0.20 | $0.19 | +5.3% |
Valuation Ratios
| P/E Ratio | 30.37 |
| Price / Book | 2.62 |
| EV / EBITDA | 13.66 |
| Dividend Yield | 0.66% |
Income Statement (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 140.81B INR | 142.03B INR | 153.85B INR | 174.60B INR | 2.56B INR | 214.39B INR | 245.88B INR | 279.16B INR | 325.54B INR | 353.47B INR |
| Cost of Revenue | 62.45B INR | 65.72B INR | 70.42B INR | 80.59B INR | 1.26B INR | 100.55B INR | 106.54B INR | 115.56B INR | 135.11B INR | 166.95B INR |
| Gross Profit | 78.36B INR | 76.30B INR | 83.43B INR | 94.01B INR | 1.30B INR | 113.84B INR | 139.34B INR | 163.61B INR | 190.43B INR | 186.52B INR |
| Research & Development | 19.55B INR | 18.27B INR | 15.61B INR | 15.41B INR | 208.4M INR | 17.48B INR | 19.38B INR | 22.87B INR | 27.38B INR | 25.31B INR |
| Selling, General & Admin | 46.37B INR | 46.91B INR | 48.89B INR | 0 | 659.9M INR | 62.08B INR | 68.03B INR | 77.20B INR | 93.87B INR | 112.34B INR |
| Operating Expenses | 64.86B INR | 64.39B INR | 62.54B INR | 78.02B INR | 866.4M INR | 84.36B INR | 82.20B INR | 95.88B INR | 118.58B INR | 137.65B INR |
| Operating Income | 13.50B INR | 11.92B INR | 20.89B INR | 15.99B INR | 431.4M INR | 29.48B INR | 57.14B INR | 67.73B INR | 71.84B INR | 48.87B INR |
| EBITDA | 24.55B INR | 23.73B INR | 35.52B INR | 41.78B INR | 534.8M INR | 45.08B INR | 74.43B INR | 88.42B INR | 96.67B INR | 83.29B INR |
| Interest Expense | 634.0M INR | 788.0M INR | 889.0M INR | 13.9M INR | 970.0M INR | 958.0M INR | 1.43B INR | 1.71B INR | 2.83B INR | 3.93B INR |
| Pre-tax Income | 14.65B INR | 14.34B INR | 22.44B INR | 18.03B INR | 355.8M INR | 32.30B INR | 60.37B INR | 71.87B INR | 76.78B INR | 57.68B INR |
| Income Tax | 2.61B INR | 4.54B INR | 3.65B INR | -1.47B INR | 123.6M INR | 8.73B INR | 15.30B INR | 16.19B INR | 19.54B INR | 13.00B INR |
| Net Income | 12.04B INR | 9.81B INR | 18.80B INR | 19.50B INR | 232.2M INR | 23.57B INR | 45.07B INR | 55.68B INR | 56.54B INR | 45.09B INR |
| EPS | $72.24 | $59.13 | $113.28 | $117.63 | $20.79 | $28.42 | $54.29 | $66.80 | $67.85 | $53.92 |
| EPS (Diluted) | $72.09 | $59.01 | $113.09 | $117.40 | $20.73 | $28.34 | $54.17 | $66.80 | $67.77 | $53.92 |
| Shares Outstanding (Diluted) | 835.0M INR | 830.9M INR | 831.0M INR | 830.4M INR | 831.6M INR | 831.7M INR | 831.9M INR | 833.5M INR | 834.3M INR | 833.3M INR |
Price
| Price | $12.32 |
| Market Cap | $10.3B |
| Exchange | NYSE |
| Country | IN |
Related companies: BMRN · EHC · ELAN · ENSG · EXEL · NBIX · RVMD
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of RDY: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks